A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame: Baseline, 60 Hours

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment.

The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = not at all sure, 1 = several days, 2 = over half the days, and 3 = nearly every day to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.

Time frame: Baseline, 60 Hours, Day 7 and 30

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Here, 'number analyzed' signifies participants evaluable for this outcome measure at specified time points.

The HAM-D Bech 6 subscale score was calculated as the sum of the following six items: depressed mood, feelings of guilt, work and activities, retardation, psychic anxiety, and general somatic symptoms. Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a scale of 0 to 100, with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame: Baseline, 60 Hours, Days 7 and 30

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Here, 'number analyzed' signifies participants evaluable for this outcome measure at specified time points.

The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicate more severe depression. A negative change from baseline indicate less severe depression. A positive change from baseline indicates more severe depression.

Time frame: Baseline, 60 Hours, Days 7 and 30

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Here, 'number analyzed'' signifies participants evaluable for this outcome measure at specified time points.

The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame: Baseline, 60 Hours

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment.

An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE was defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.

Time frame: Up to 30 days

Population: Safety population included all randomized participants who started the study drug infusion.

The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments, and by definition, was evaluated against baseline conditions. CGI-I response was defined as having a CGI-I score of very much improved or much improved.

Time frame: 60 Hours, Days 7 and 30

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Here, 'number analyzed'' signifies participants evaluable for this outcome measure at specified time points.

The HAM-D remission was defined as having a HAM-D total score of less than or equal to (\<=)7. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame: 60 Hours, Days 7, and 30

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Here, 'number analyzed'' signifies participants evaluable for this outcome measure at specified time points.

The HAM-D response was defined as having a 50 percent (%) or greater reduction from baseline in HAM-D total score. The HAM-D total score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The total score can range from 0 to 52, and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame: 60 Hours, Days 7 and 30

Population: Efficacy population included the subset of the all randomized participants who started the study drug infusion and who had a valid baseline HAM-D assessment and at least one post-baseline HAM-D assessment. Here, 'number analyzed' signifies participants evaluable for this outcome measure at specified time points.